Marks First In-Human Clinical Study Demonstrating the Value of Immuno-Pharmacodynamics in the Assessment of Radioligand Therapy  Novigenix AI Liquid Biopsy Platform Identifies Immune Activation Patterns Associated with Radioligand Therapy Response in Gastroenteropancreatic Neuroendocrine Tumors Epalinges, Switzerland — April 14, 2026  — Novigenix AI, a leader in AI-driven healthcare solutions, today announced the presentation of